Abstract

BackgroundWidespread implementation of Alzheimer’s disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF).MethodsHere, CSF collection and storage protocols were optimized for measurements of β-amyloid (Aβ). We investigated the effects of (1) storage temperature, (2) storage time, (3) centrifugation, (4) sample mixing, (5) blood contamination, and (6) collection gradient on CSF levels of Aβ. For each study participant, we used fresh CSF directly collected into a protein low binding (LoB) tube that was analyzed within hours after lumbar puncture (LP) as standard of truth. Aβ42 and Aβ40 were measured in de-identified CSF samples using EUROIMMUN and Mesoscale discovery assays.ResultsCSF Aβ42 and Aβ40 were stable for at least 72 h at room temperature (RT), 1 week at 4 °C, and 2 weeks at − 20 °C and − 80 °C. Centrifugation of non-blood-contaminated CSF or mixing of samples before the analysis did not affect Aβ levels. Addition of 0.1–10% blood to CSF that was stored at RT without centrifugation led to a dose- and time-dependent decrease in Aβ42 and Aβ40, while Aβ42/Aβ40 did not change. The effects of blood contamination were mitigated by centrifugation and/or storage at 4 °C or − 20 °C. Aβ levels did not differ between the first to fourth 5-ml portions of CSF.ConclusionsCSF can be stored for up to 72 h at RT, 1 week at 4 °C, or at least 2 weeks at either − 20 °C or − 80 °C before Aβ measurements. Centrifugation of fresh non-blood-contaminated CSF after LP, or mixing before analysis, is not required. In case of visible blood contamination, centrifugation and storage at 4 °C or − 20 °C is recommended. After discarding the first 2 ml, any portion of up to 20 ml of CSF is suitable for Aβ analysis. These findings will be important for the development of a clinical routine protocol for pre-analytical handling of CSF.

Highlights

  • Widespread implementation of Alzheimer’s disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF)

  • In CSF samples from all study participants analyzed on the day of collection, the median values for Aβ42EI, Aβ40EI, Aβ42/Aβ40EI, Aβ42MSD, Aβ40MSD, and Aβ42/Aβ40MSD were 747 pg/ml (353–1892 pg/ml), 8343 pg/ml (3541–12933 pg/ml), 0.13 (0.05–0.23), 511 pg/ml (198–1554 pg/ml), 6249 pg/ml (2813–12094 pg/ml), and 0.11 (0.04–0.18), respectively (Additional file 1: Figure S7)

  • Using the low binding (LoB) tube and fresh CSF analyzed within hours after lumbar puncture (LP) as the standard of truth, we demonstrate that centrifugation after LP does not affect Aβ42 and Aβ40 levels in non-hemorrhagic CSF samples stored at room temperature (RT), 4 °C, and − 20 °C for up to 2 weeks after collection

Read more

Summary

Introduction

Widespread implementation of Alzheimer’s disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF). Cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers, β-amyloid 42 (Aβ42) and tau, have been incorporated into the clinical research criteria for AD diagnosis proposed by the US National Institute on Aging–Alzheimer’s Association (NIA-AA) [1] and International Working Group (IWG) for New Research Criteria for the Diagnosis of AD [2] to be able to implement CSF AD biomarkers worldwide, we need to have (i) appropriate use criteria in place, (ii) high precision methods to determine CSF AD biomarker levels with very low within and between laboratory variations, Janelidze et al Alzheimer's Research & Therapy (2019) 11:63 biomarker levels between centers is due to the differences in pre-analytical procedures, and the standardization of biomarker measurements and establishment of global cutoffs will critically depend on the development of a unified pre-analytical protocol. To limit potential effects of analytical variables, Aβ42 and Aβ40 were measured using 2 different immunoassays, EUROIMMUN (EI) and Mesoscale discovery (MSD)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call